Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SNTI Stock Forecast 2026-2027
$0.97
Current Price
$30.07M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SNTI Price Targets
+1,453.8%
To High Target of $15.00
+1,143.0%
To Median Target of $12.00
+521.5%
To Low Target of $6.00
SNTI Price Momentum
+2.1%
1 Week Change
0.0%
1 Month Change
-74.7%
1 Year Change
-6.7%
Year-to-Date Change
-75.1%
From 52W High of $3.88
+25.4%
From 52W Low of $0.77
📊 TOP ANALYST CALLS
Did SNTI Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Senti Biosciences is one of their latest high-conviction picks.
Latest SNTI Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, SNTI has a bullish consensus with a median price target of $12.00 (ranging from $6.00 to $15.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.97, the median forecast implies a 1,143.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SNTI Analyst Ratings
4
Buy
0
Hold
0
Sell
SNTI Price Target Range
Low
$6.00
Average
$12.00
High
$15.00
Current: $0.97
Latest SNTI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SNTI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $12.00 |
| Mar 30, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 9, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 21, 2025 | Leerink Partners | Outperform | Initiates | $N/A | |
| Oct 14, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Aug 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 12, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jun 6, 2025 | Laidlaw & Co. | Buy | Initiates | $N/A | |
| May 2, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 4, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 2, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 15, 2023 | Chardan Capital | Buy | Reiterates | $N/A | |
| May 11, 2023 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 24, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Mar 23, 2023 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 30, 2023 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 27, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Dec 16, 2022 | JP Morgan | Neutral | Initiates | $N/A | |
| Oct 7, 2022 | Morgan Stanley | Equal-Weight | Initiates | $N/A | |
| Sep 29, 2022 | B of A Securities | Buy | Initiates | $N/A |
Senti Biosciences Inc. (SNTI) Competitors
The following stocks are similar to Senti Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Senti Biosciences Inc. (SNTI) Financial Data
Senti Biosciences Inc. has a market capitalization of $30.07M with a P/E ratio of 4.3x. The company generates $38,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -27.3% quarter-over-quarter, while maintaining an operating margin of -71,362.5% and return on equity of -1,099.3%.
Valuation Metrics
Market Cap
$30.07M
Enterprise Value
$42.53M
P/E Ratio
4.3x
PEG Ratio
0.0x
Price/Sales
799.4x
Growth & Margins
Revenue Growth (YoY)
-27.3%
Gross Margin
N/A
Operating Margin
-71,362.5%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+55.6%
Current Ratio
1.0x
Debt/Equity
516.9x
ROE
-1,099.3%
ROA
-119.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Senti Biosciences Inc. (SNTI) Business Model
About Senti Biosciences Inc.
What They Do
Develops next-generation cell and gene therapies.
Business Model
Senti Biosciences generates revenue by engineering and commercializing innovative therapies that target complex diseases, particularly in oncology. The company utilizes its synthetic biology platform to create genetic circuits that enhance the efficacy and safety of treatments, offering customizable solutions for patients.
Additional Information
The company aims to transform treatment paradigms in healthcare by advancing precision medicine. Their focus on intelligent therapeutics positions them as a key player in the biotechnology sector, with a commitment to improving patient outcomes through advanced genetic engineering.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
39
CEO
Dr. Timothy K. Lu M.D., Ph.D.
Country
United States
IPO Year
2021
Website
www.sentibio.comSenti Biosciences Inc. (SNTI) Latest News & Analysis
Latest News
Quick Summary
A company secured up to $40 million in financing and received positive FDA feedback for a pivotal trial of SENTI-202 for Relapsed/Refractory Acute Myeloid Leukemia, reducing quarterly net loss and cash burn.
Why It Matters
Secured financing boosts liquidity, FDA support enhances trial prospects for SENTI-202, and reduced losses signal operational efficiency, all positively impacting investor confidence and potential returns.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Senti Bio will advance a single-arm multi-center trial for SENTI-202 after positive Phase 1 results, focusing on achieving MRD-negative complete remissions.
Why It Matters
Senti Bio's decision to advance with a registrational trial for SENTI-202, backed by positive Phase 1 results, could enhance its market position and attract investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Senti Biosciences, Inc. (Nasdaq: SNTI) will have CEO Timothy Lu present at the AACR Annual Meeting 2026 from April 17-22 in San Diego, focusing on its Gene Circuit platform for cell and gene therapies.
Why It Matters
Senti Biosciences' CEO presenting at a major conference highlights the company's visibility and potential breakthroughs in gene therapy, attracting investor interest and possibly impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Senti Biosciences (Nasdaq: SNTI) published research in Cell Systems on improved CAR circuits for T and NK cells, enhancing precision in cancer therapies, complementing positive clinical data for SENTI-202.
Why It Matters
Senti Biosciences' peer-reviewed research enhances its credibility and showcases advancements in its therapies, potentially boosting investor confidence in its future growth and clinical success.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
2 months ago
Quick Summary
Senti Biosciences (Nasdaq: SNTI) reported its Q4 and full-year 2025 financial results and highlighted recent developments in its gene therapy pipeline.
Why It Matters
Senti Bio's financial results and pipeline updates signal its progress in biotechnology, impacting future valuations and investor sentiment in the sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
2 months ago
Quick Summary
Senti Biosciences, Inc. (SNTI) will present clinical and translational data from its SENTI-202 program at the Innate Killer Conference on March 24-25, 2026, in San Diego.
Why It Matters
Senti Biosciences' upcoming presentations on clinical data could influence investor sentiment and stock performance, highlighting advancements in their Gene Circuit platform and potential market impact.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SNTI Stock
What is Senti Biosciences Inc.'s (SNTI) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Senti Biosciences Inc. (SNTI) has a median price target of $12.00. The highest price target is $15.00 and the lowest is $6.00.
Is SNTI stock a good investment in 2026?
According to current analyst ratings, SNTI has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SNTI stock?
Wall Street analysts predict SNTI stock could reach $12.00 in the next 12 months. This represents a 1,143.0% increase from the current price of $0.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Senti Biosciences Inc.'s business model?
Senti Biosciences generates revenue by engineering and commercializing innovative therapies that target complex diseases, particularly in oncology. The company utilizes its synthetic biology platform to create genetic circuits that enhance the efficacy and safety of treatments, offering customizable solutions for patients.
What is the highest forecasted price for SNTI Senti Biosciences Inc.?
The highest price target for SNTI is $15.00 from at , which represents a 1,453.8% increase from the current price of $0.97.
What is the lowest forecasted price for SNTI Senti Biosciences Inc.?
The lowest price target for SNTI is $6.00 from at , which represents a 521.5% increase from the current price of $0.97.
What is the overall SNTI consensus from analysts for Senti Biosciences Inc.?
The overall analyst consensus for SNTI is bullish. Out of 2 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are SNTI stock price projections?
Stock price projections, including those for Senti Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 11:50 AM UTC